Royalty Pharma
RPRX
319 hedge funds and large institutions have $12.1B invested in Royalty Pharma in 2022 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 127 increasing their positions, 88 reducing their positions, and 19 closing their positions.
416% more call options, than puts
Call options by funds: $77.9M | Put options by funds: $15.1M
189% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 19
44% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 88
13% more funds holding
Funds holding: 283 → 319 (+36)
2.27% more ownership
Funds ownership: 66.86% → 69.13% (+2.3%)
1% less capital invested
Capital invested by funds: $12.2B → $12.1B (-$159M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
Top Sellers
RPRX Hedge Fund Activity: Q3 2022 in Review
319 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2022, worth a combined $12.1B — down 1.3% from $12.2B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new RPRX positions and 19 closed out — a net gain of 36 holders — while 127 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $299M. The largest seller was Adage Capital Partners, cutting an estimated $365M.
- 319 institutional investors held Royalty Pharma (RPRX) as of Q3 2022, up from 283 in Q2 2022.
- Funds reported $12.1B of Royalty Pharma stock for Q3 2022, down 1.3% quarter-over-quarter.
- 55 funds opened new Royalty Pharma positions in Q3 2022 and 19 closed out, a net change of +36 holders.
- The largest Royalty Pharma buyer in Q3 2022 was Fidelity Investments, an estimated $299M added.
- The largest Royalty Pharma seller in Q3 2022 was Adage Capital Partners, an estimated $365M sold.
Based on aggregated 13F filings for Q3 2022.